The AIDA Knockout Jurkat Polyclonal Cells are a CRISPR/Cas9-edited polyclonal knockout cell population generated from the Jurkat human T lymphocyte cell line. This product employs CRISPR/Cas9-mediated gene disruption to inactivate the AIDA gene, yielding a mixed population of cells carrying diverse loss-of-function alleles. The polyclonal format avoids the selection bottlenecks associated with clonal isolation, providing a more representative model for pooled functional studies and bulk assays where targeting heterogeneity is acceptable. It is intended for investigating AIDA function in Wnt signaling and T cell biology.
Jurkat cells originate from an acute T cell leukemia patient and serve as a well-established model for T cell receptor (TCR) signaling, apoptosis, and HIV research. Their immortalized nature and robust growth characteristics make them amenable to genetic manipulation and high-throughput applications. Importantly, Jurkat cells retain key signaling modules of normal T cells, allowing dissection of pathways that intersect with Wnt/??-catenin signaling, including TCR-driven activation cascades and cytokine production.
AIDA (Axin Interactor, Dorsalization Associated) is a negative regulator of the canonical Wnt/??-catenin pathway. It exerts its effects by binding to AXIN1 and Dishevelled proteins (DVL1/2/3) within the ??-catenin destruction complex, reinforcing its activity and promoting ??-catenin degradation. This action opposes WNT ligand signaling through Frizzled receptors and LRP5/6 co-receptors, thereby dampening TCF/LEF-dependent transcription of targets such as MYC, CCND1, and AXIN2. Consequently, AIDA acts as an endogenous brake on Wnt-mediated gene expression, fine-tuning pathway output in normal and malignant contexts.
In Jurkat cells, loss of AIDA is predicted to relieve inhibition on Wnt signaling, leading to increased stability of ??-catenin and heightened expression of Wnt target genes. This dysregulation can influence T cell functional programs, potentially modulating IL-2 production and proliferation downstream of TCR engagement. Given the emerging role of Wnt signaling in T cell development and leukemia, these polyclonal knockout cells offer a unique model to study how aberrant Wnt activation contributes to T cell malignancy and to test interventions that target the pathway.
Applications include TOPFlash/FOPFlash dual-luciferase reporter assays to quantify ??-catenin-driven transcription, Western blot analysis of ??-catenin and phospho-LRP6 levels, and RT-qPCR profiling of Wnt-responsive genes. Co-immunoprecipitation can confirm the absence of AIDA-AXIN1 or AIDA-DVL interactions, while flow cytometry provides single-cell assessment of ??-catenin accumulation. Functional T cell activation studies using IL-2 ELISA can probe the intersection between Wnt and TCR signaling. This polyclonal knockout product thus supports multifaceted research in signal transduction, cancer biology, and immunology. For additional details or bulk orders, please contact Ascent Research.
